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Antiphospholipid syndrome (APS) is primarily considered
to be an autoimmune pathological condition that is also
referred to as "Hughes syndrome". It is characterized by
arterial and/or venous thrombosis and pregnancy pathologies
in the presence of anticardiolipin antibodies and/or lupus
anticoagulant. APS can occur either as a primary disease or
secondary to a connective tissue disorder, most frequently
systemic lupus erythematosus (SLE). Damage to the nervous
system is one of the most prominent clinical constellations
of sequelae in APS and includes (i) arterial/ venous throm-
botic events, (ii) psychiatric features and (iii) other non-
thrombotic neurological syndromes. In this overview we
compare the most important vascular ischemic (occlusive)
disturbances (VIOD) with neuro-psychiatric symptomatics,
together with complete, updated classifications and hypotheses
for the etio-pathogenesis of APS with underlying clinical and
laboratory criteria for optimal diagnosis and disease manage-
ment.
Key Words: Antiphospholipid syndrome, antiphospholipid
antibodies, ischemic, occlusive, neurological, classifications,
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INTRODUCTION
Antiphospholipid (antibody) syndrome (APS)
is a pathological condition that is also referred to
as "Hughes syndrome." It originates from excess
accumulation of blood clots by antiphospholipid
antibodies (aPLs). The syndrome may occur as a
primary condition (primary APS) or along with
the autoimmune disease, systemic lupus erythe-
matosus (SLE or lupus). SLE is a chronic disease
that affects certain organs, blood vessels, or the
skin. The main signs of APS include blotchy
skin, migraine, memory loss, fatigue, deep vein
thrombosis, pulmonary embolism, and stroke.
Primary APS may affect heart valves and
present with such damage in 30% of patients. In
pregnant women with APS, miscarriages may
occur.
In this overview, we present an up-to-date
description and synthesis of the main vascular
ischemic (occlusive) diseases (VIOD) with neuro-
psychiatric symptomatics in APS. The recognition
that a number of SLE manifestations have a
thrombotic rather than an inflammatory basis can
be considered one of the most important recent
contributions to rheumatology and immunology.
The "anticardiolipin syndrome" described by
Graham Hughes in the 1980s,
1 which was
subsequently renamed antiphospholipid (Hughes)
syndrome, appeared as a frequent condition in
patients with SLE
2 but also was present in others
without SLE or other autoimmune diseases. In
such cases it was termed a "primary" APS (PAPS)
3.
Almost 20 years after its definition, APS has
crossed over into many fields of medicine. How-
ever, the full spectrum of the syndrome has yet
to be defined, and significant advances in the
diagnosis and management of patients with APS
have been made. In addition, a consensus about
very important questions, such as the use of
alternative tests for anticardiolipin (aCL) anti-
bodies and lupus anticoagulant (LA) assays, the
treatment of pregnancy failure, or the intensity
of anticoagulant therapy, has not yet been
achieved.
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CLASSIFICATIONS, ETIO-PATHOGENESIS
AND CRITERIA FOR APS
An expert’s council at the Eighth International
Symposium on antiphospholipid antibodies at
Sapporo (Japan)
4 has recently established the
preliminary criteria for the classification of
definite APS (Table 1). Clinical criteria include
arterial, venous, and/or small vessel thrombosis
as well as recurrent (three or more) miscarriage,
one fetal death or prematurity due to severe
preeclampsia or placental insufficiency. Labora-
tory criteria only consider aCL levels at medium to
high titers or LA if any of them are positive on two
separate occasions at least six weeks apart. These
criteria were established for research but also
provide a working basis for clinical diagnosis. The
criteria have been validated in a cross- sectional
trial of 243 patients with primary and secondary
APS, SLE, or lupus-like disease. They have shown
a 71% sensitivity and a 98% specificity with
positive and negative predictive values of 95% and
88%, respectively, to correctly classify patients with
APS.
5 Recently, a revised version of the APS
classification criteria has been presented (Table 1).
Antiphospholipid antibody testing
Laboratory work is crucial in the identification
of patients with APS. Clinical suspicion based on
recurrent thrombosis, miscarriage or other
features of APS must be always confirmed by
positive tests that detect the presence of aPLs.
Ideally, these tests must have a high sensitivity
and specificity. In addition, standardization and a
high level of intra and inter-laboratory repro-
ducibility are desirable, so patients tested at
different times and places do not exhibit different
results.
The two most standardized techniques for the
detection of aPLs are the enzyme-linked immuno-
sorbent assay (ELISA) for aCL and the coagulation-
based assays for LA. These two methods do not
necessarily identify the same antibodies and are
not completely coincident (up to 30% of patients
exhibit positivity to only one of them), making it
necessary to routinely determine both. It is signi-
ficant to note that aCL assays, which use 2- β
glycoprotein I ( 2GPI) as a cofactor, detect β
antibodies of the IgG, IgM and IgA isotypes,
6 but
only the former two have been adopted into
clinical practice as laboratory criteria by the
original Sapporo panel.
4 Moreover, persistent
positivity (of aCL, LA or both) and medium-to-
high levels of aCL on a semi-quantitative scale are
required to consider them clinically significant.
The LA test consists of a combination of
coagulation assays which must demonstrate that
the prolongation of phospholipid-dependent tests
corrects by adding reagents with a high con-
centration of phospholipids but not by adding
normal plasma
7. The most widely used tests
include a modified activated partial throm-
boplastin time (APTT), the dilute Russell’s Viper
Venom Time (dRVVT) and the Kaolin Clotting
Time (KCT). Recent guidelines for the detection of
LA have been published.
8
Various assays for the detection of antibodies to
other phospholipids or phospholipid-binding pro-
teins (phosphatidylserine, 2GPI, prothrom β bin,
protein C, etc.) are available, but they are less
standardized and are not recommended for
sustaining clinical decisions in daily practice.
9
According to these results, the role of these
more specific but less sensitive alternative tests
should be to confirm a diagnosis of APS in the
context of atypical manifestations or borderline
aCL and LA results, rather than to test patients
with APS features who are aCL-negative. In this
sense it was found that testing for anti- 2GPI β
does not identify additional patients with APS
among those with recurrent miscarriage or fetal
death who are negative for aCL.
10
Etiology and pathogenetic mechanisms
APS is mainly considered an autoimmune
disorder where a vascular thrombosis and/or re-
current pregnancy pathologies are observed in
patients with laboratory evidence for antibodies
against phospholipids or phospholipid-binding
protein cofactors. As mentioned above, the clinical
manifestations of the syndrome include venous
and arterial thromboses and embolisms, dissemin-
ated large and small vessel thromboses with
accompanying multi-organ ischaemia and infarc-
tion, stroke, premature coronary artery disease,
and spontaneous pregnancy losses.
11Table 1. Classification of APS
Criteria description
A) Sapporo criteria for APS (1999)
Clinical
1. Vascular thrombosis
One or more documented episodes of arterial, venous and/or small vessel thrombosis.
2. Pregnancy morbidity:
One or more unexplained deaths of a morphologically normal foetus at or beyond the 10
th week of gestation, or
One or more premature births of a morphologically normal neonate at or before the 34
th week of gestation due to severe
pre-eclampsia or placental insufficiency, or Three or more unexplained consecutive spontaneous abortions before the 10
th week
of gestation.
Laboratory
1. Anticardiolipin antibody
Anticardiolipin antibody (aCL) of IgG and/or IgM isotype in medium or high titreon 2 or more occasions at least 6 weeks
apart.
2. Lupus anticoagulant
Lupus anticoagulant (LA) present in plasma on 2 or more occasions at least 6 weeks apart
B) Revised criteria for APS (2006)
APS is present if at least one of the clinical criteria and one of the laboratory criteria that follow are met*:
Clinical
1. Vascular thrombosis
One or more clinical episodes of arterial, venous, or small vessel thrombosis§, in any tissue or organ. Thrombosis must be
confirmed by objective validated criteria (i.e. unequivocal findings of appropriate imaging studies or histopathology). For
histopathologic confirmation, thrombosis should be present without significant evidence of inflammation in the vessel wall.
2. Pregnancy morbidity
(a) One or more unexplained deaths of a morphologically normal foetus at or beyond the 10
th week of gestation, with normal
foetal morphology documented by ultrasound or by direct examination of the foetus, or defined according to standard
definitions
(b) One or more premature births of a morphologically normal neonate before the 34
th week of gestation because of: (i)
eclampsia or severe pre-eclampsia or (ii) recognized features of placental insufficiency, or
(c) Three or more unexplained consecutive spontaneous abortions before the 10
th week of gestation, with maternal anatomic
or hormonal abnormalities and paternal and maternal chromosomal causes excluded.
Laboratory criteria
§,
1. Lupus anticoagulant (LA) present in plasma, on two or more occasions at least 12 weeks apart, detected according to the
guidelines of the International Society on Thrombosis and Haemostasis (Scientific Subcommittee on LAs/phospholipid-
dependent antibodies).
2. Anticardiolipin (aCL) antibody of IgG and/or IgM isotype in serum or plasma, present in medium or high titre (i.e. > 40
GPL or MPL, or > the 99
th percentile), on two or more occasions, at least 12 weeks apart, measured by a standardized ELISA.
3. Anti-b2 glycoprotein-I antibody of IgG and/or IgM isotype in serum or plasma (in titre > the 99
th percentile), present on two
or more occasions, at least 12 weeks apart, measured by a standardized ELISA, according to recommended procedures.
*Definite antiphospholipid syndrome is considered to be present if at least one clinical and one laboratory criteria are met.
Classification of APS should be avoided if less than 12 weeks or more than 5 years separate the positive aPL test and the clinical manifestation.
Two subgroups of APS patients should be recognized, according to: (a) the presence, and (b) the absence of additional risk factors for thrombosis.
Indicative (but not exhaustive) such cases include: age (> 55 in men, and > 65 in women), and the presence of any of the established risk factors
for cardiovascular disease (hypertension, diabetes mellitus, elevated LDL or low HDL cholesterol, cigarette smoking, family history of premature
cardiovascular disease, body mass index > 30, microalbuminuria, estimated GFR < 60 mL min-1), inherited thrombophilias, oral contraceptives,
nephrotic syndrome, malignancy, immobilization, and surgery. Thus, patients who fulfil criteria should be stratified according to contributing causes
of thrombosis. A thrombotic episode in the past could be considered as a clinical criterion, provided that thrombosis is proved by
appropriatediagnostic means and that no alternative diagnosis or cause of thrombosis is found. Superficial venous thrombosis is not included in the
clinical criteria. Generally accepted features of placental insufficiency include: (i) abnormal or non-reassuring foetal surveillance test(s), e.g. a non-
reactive non-stress test, suggestive of foetalhypoxemia, (ii) abnormal Doppler flow velocimetry waveform analysis suggestive of foetal hypoxemia,
e.g. absent end-diastolic flow in the umbilical artery, (iii) oligohydramnios, e.g. an amniotic fluid index of 5 cm or less, or (iv) a postnatal birth weight
less than the 10
th percentile for the gestational age.
§ In studies of populations of patients who have more than one type of pregnancy morbidity, investigators are strongly encouraged to stratify groups
of subjects according to a, b, or c below.
Investigators are strongly advised to classify APS patients in studies into one of the following categories: I, more than one laboratory criteria present
(any combination);IIa, LA present alone; IIb, aCL antibody present alone; IIc, anti-b2 glycoprotein-I antibody present alone.
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The aetiology of APS is multifactorial,
11,12 and
an exact, single cause cannot always be deter-
mined. A number of hypotheses have been pro-
posed to explain the pathophysiology of cellular,
molecular, and genetic involvement in APS, as
well as the pathogenesis by which the presence of
antibodies reinforces its clinical appearance. The
most important conjectures are summarized here.
(i) The first pathogenetic pathway implicates an
activation of the endothelium. The antiphospho-
lipid antibodies bind and activate the endothelial
cells, whereas the expression of adhesion mole-
cules is increased together with a higher secretion
of cytokines and activated prostacyclin metabo-
lism. aPLs recognize 2-glycoprotein I as being β
bound to resting endothelial cells, although the
basis for the interaction of 2GPI with viable β
endothelial cells remains unclear.
(ii) The second hypothesis indicates an oxidant-
mediated injury of the vascular endothelium. Oxi-
dized low-density lipoprotein (LDL) is absorbed
by macrophages thus leading to macrophage
activation and subsequent damage to endothelial
cells. Autoantibodies to oxidized LDL appear in
association with aCL, and it is possible that a
cross-reaction of aCL with oxidized LDL could
take place. It is important that aCLs bind to
oxidized cardiolipin-recognizing oxidized phos-
pholipids, phospholipid-binding proteins, or both.
(iii) The third mechanism involves the interference
of aPLs with or the modulation of the function of
phospholipid-binding proteins involved in the
coagulation regulatory system (it has been
suggested that 2GPI may represent a natural β
anticoagulant). The high affinity of the aPL/β
2GPI complex for phospholipid membranes is
considered a critical step in the mechanism of
APS.
11 For example, molecular "mimicry" between
2GPI related synthetic peptides and structures β
within bacteria, viruses (e.g., cytomegalovirus)
and the tetanus toxoid could explain the appea-
rance of APS in such conditions (see below).
13
Additional pathways where aPLs interfere with
the regulation of protein C, annexin V, prothrom-
bin, and tissue factor have also been suggested.
12,13
(iv) The fourth approach to thrombosis in APS is
related to heparin-induced thrombocytopenia (a
thrombosis in multiple arterial and venous beds is
observed in both pathologies). In heparin-induced
thrombocytopenia, a prior cardiovascular disease
determines the site of thrombosis while a high
recurrence rate of similar thrombotic events is
observed in APS. Notably, a "second hit" (e.g.,
vascular damage) may be needed for thrombosis
to appear. However, it is not very clear which
cellular phospholipids and phospholipid-binding
proteins are bound by aPLs in vivo. The absence
of anionic phospholipids on the cell surface and
the lack of reactivity of aPLs with intact cells
suggest that cell membrane injury may be
necessary for aPLs to bind. Indeed, some aPLs
bind to activated platelets and apoptotic cells after
the normal asymmetric distribution of membrane
phospholipids have been lost and the anionic
phospholipids have been exposed on the cell
surface. Both the binding to and induction of aPLs
by apoptotic cells are dependent on 2GPI; β
(v) The fifth "triggering" hypothesis, which has
been emphasized recently although it is not
always apparent in APS,
13,14 is based on the
abovementioned molecular mimicry with infec-
tions and/or other pathologic events. Many infec-
tions may be accompanied by increases in aPLs
and, frequently, by clinical APS manifestations
(e.g., 18% skin infections, 17% human immunode-
ficiency virus infection, 14% pneumonia, 13%
hepatitis C virus infections and 10% urinary tract
infections). Other, less common infections in APS
include mycoplasma, pulmonary tuberculosis,
malaria, Pneumocystis carinii, and leptospirosis.
Although IgM isotypes of aCLs seem to be the
primary products, increases in IgG have also been
detected. Moreover, even though the initial re-
ports indicated that infection-associated aPLs
were 2GPI-independent and nonpathogenic, β
several later studies clearly documented their
reactivity with 2GPI. β
14 It appears that APS in
infection is also developed by a two-hit mechani-
sm, which is similar to the vascular damage
described previously. It is also possible that the
infections occurred long before the autoimmune
manifestation emerged. In particular, it was
observed that ‘‘triggering’’ factors become incre-
asingly apparent in catastrophic APS, and these
were present in 51% of cases in a recent analysis
by Cervera et al. in 2003 [as cited in 14]. Such
factors included trauma (surgical, both major and
minor), anticoagulation withdrawal, a variety ofAntiphospholipid Syndrome and Ischemic Diseases
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carcinomas, and, most importantly and com-
monly, infections, which were described in 24% of
these patients.
MAIN CLINICAL FEATURES OF APS
The "classical" clinical features associated with
APS, as originally introduced, include recurrent
thrombosis and pregnancy losses. The main pregnancy-
related complications consist of maternal com-
plications: women with aPLs are more likely to
develop a postpartum cardiopulmonary syndrome,
15,16 chorea gravidarum
17, postpartum cerebral
infarct following aspirin withdrawal
18, and mater-
nal death
19. It is suggested that clinical thrombosis
is associated with pregnancy and the postpartum
period pathologies. The other manifestation is the
so-called "HELLP Syndrome." It was found that
preeclamptic women may present with hemolysis
(H), elevated liver enzymes (EL) and a low
platelet count (P). Notably, HELLP syndrome may
also occur in the absence of severe preeclampsia.
Although typically encountered during preg-
nancy, HELLP syndrome may be atypical and
persist into the postpartum period. There are
doubts as to whether this syndrome represents a
variant of preeclampsia or whether it represents a
hypercoagulable state with thrombotic microan-
giopathy, and this is the reason we described
these obstetric symptomatics separately from the
rest of the clear vaso-ischemic pathologies. Earlier
evidence for an association between this syndrome
and aPLs was published in 1994
20 with demon-
strated aCL antibodies and a refractory appearance
despite delivery, corticosteroids and anticoagulation
therapy. The clinical course also included a
macular rash that extended to the palms. The
placental pathology and skin biopsies revealed
diffuse deposition of fibrin with small vessel
thrombi; these were resolved by plasmapheresis,
and it was postulated that aPLs may have
contributed to the refractoriness. Notably, early
(35.4%) or late fetal loss (16.9%), premature births
(10.6%) and preeclampsia (9.5%) are the most
frequent fetal and obstetric manifestations of
APS.
21
As previously mentioned, the classical clinical
picture of APS is characterized by venous and
arterial thromboses, fetal losses and thrombo-
cytopenia in the presence of aPLs, LA, aCL or
antibodies to the protein "co-factor" beta 2
glycoprotein 1. APS can be found in patients
having neither clinical nor laboratory evidence of
another definable condition (primary APS), or it
may be associated with other diseases (secondary
APS, e.g., after SLE). Single vessel involvement or
multiple vascular occlusions may give rise to a
wide variety of presentations as summarized
below, beyond the obstetric symptomatics alone.
Any combination of vascular occlusive events
may occur in the same individual (Table 2). The
time interval between these events can also vary
considerably, from weeks to months or even
years. Rapid chronological occlusive events,
occurring over days to weeks, have been referred
to as "catastrophic" APS (CAPS).
22
The percent (relative) cumulative distribution of
APS-related pathologies is presented in Table 2 as
an example based on a population cohort of 1000
APS patients. According to the largest survey of
APS patients to date,
21 deep vein thrombosis,
sometimes accompanied by pulmonary embolism,
is the most frequently reported manifestation of
this syndrome (38.9%). Conversely, cerebrovascu-
lar accidents, either stroke (19.8%) or transient
ischemic attacks (11.1%), are the most common
arterial thrombotic manifestations. In addition,
several other clinical features are relatively co-
mmon in these patients, i.e. thrombocytopenia
(29.6%), livedo reticularis (24.1%), heart valve
lesions (11.6%), hemolytic anemia (9.7%), epilepsy
(7%), myocardial infarction (5.5%), leg ulcers
(5.5%), and amaurosis fugax (5.4%). Below we
summarize and describe the main patterns of the
most important vaso-ischemic (occlusive) diseases
(VIOD) in APS.
APS AND VASO-ISCHEMIC (OCCLUSIVE)
DISEASES WITH NEUROPSYCHIATRIC
SYMPTOMATICS
For the purpose of this overview, we describe
here all VIODs in APS, and later we emphasize
those with prevalently-expressed neuropsychiatric
symptomatics. Since the cardiovascular and cere-
brovascular pathologies in APS are potentially theTable 2. APS and Cumulative Incidence of Main Clinical Diagnoses (× 1000 Patients)
Diagnoses* n % Total (%)
1. Osteoarticular 68.2
1.1 Arthralgia
1.2 Arthritis
1.3 Avascular necrosis of bone
387
271
24
38.7
27.1
2.4
2. Neurological 65.8
2.1 Migraine
2.2 Stroke
2.3 Transient ischemic attack
2.4 Epilepsy
2.5 Multi-infarct dementia
2.6 Chorea
2.7 Acute encephalopathy
2.8 Transient amnesia
2.9 Cerebral venous thrombosis
2.10 Cerebellar ataxia
2.11 Transverse myelopathy
2.12 Hemiballismus
202
198
111
70
25
13
11
7
7
7
4
3
20.2
19.8
11.1
7.0
2.5
1.3
1.1
0.7
0.7
0.7
0.4
0.3
3. Peripheral thrombosis 63.7
3.1 Deep vein thrombosis
3.2 Superficial thrombophlebitis in legs
3.3 Arterial thrombosis in legs
3.4 Venous thrombosis in arms
3.5 Arterial thrombosis in arms
3.6 Subclavian vein thrombosis
3.7 Jugular vein thrombosis
389
117
43
34
27
18
9
38.9
11.7
4.3
3.4
2.7
1.8
0.9
4. Cutaneous 39.6
4.1 Livedo reticularis
4.2 Ulcers lesions
4.3 Pseudovasculitic
4.4 Digital gangrene
4.5 Cutaneous necrosis
4.6 Splinter hemorrhages
241
55
39
33
21
7
24.1
5.5
3.9
3.3
2.1
0.7
5. Haematological 39.3
5.1 Thrombocytopenia (< 100,000/ l) μ
5.2 Haemolytic anaemia
296
97
29.6
9.7
6. Cardiac 26.9
6.1 Valve thickening/dysfunction
6.2 Myocardial infarction
6.3 Angina
6.4 Myocardiopathy
6.5 Vegetations
6.6 Coronary bypass rethrombosis
6.7 Intracardiac thrombus
116
55
27
29
27
11
4
11.6
5.5
2.7
2.9
2.7
1.1
0.4
7. Pulmonary 19.7
7.1 Pulmonary embolism
7.2 Pulmonary hypertension
7.3 Pulmonary microthrombosis
7.4 Fibrosant alveolitis
7.5 Other (ARDS*, pulmonary haemorrhage, pulmonary artery thrombosis)
141
22
15
12
7
14.1
2.2
1.5
1.2
0.7
8. Ophthalmologic 8.8
9. Intra-abdominal (renal, gastrointestinal, hepatic, etc.) 6.9
10. E.N.T. (nasal septum perforation) 0.8
*Obstetric diagnoses are not included. ARDS, adult respiratory distress syndrome. With modifications from Asherson RA, Cervera R. Unusual
manifestations of the antiphospholipid syndrome (http://www.rheuma21st.com/ downloads/cutting_edge_unsual_aps_asherson.pdf) Cutting Edge
Reports, Rheuma21st, 2002.
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Table 3. Classifications of Cardio- and Cerebrovascular Diseases (ICD-VIII, IX and X Revisions)*
ICD-VIII ICD-IX ICD-X
Cardio-vascular diseases
Rheumatic heart disease 393 - 398 Chronic rheumatic heart disease I05 - I09 Rheumatic heart disease
Ischaemic heart disease
410-414 Ischaemic heart disease 410 - 414 Ischaemic heart disease I20 - I25 Ischaemic heart disease
410 Acute myocardial infarction 410 Acute myocardial infarction I21, I22 Acute myocardial infarction
411 Other acute and sub-acute forms of
ischaemic heart disease
411 Other acute and sub-acuteforms
of ischaemic heart disease I20.0 Other acute ischaemic heart
disease
412 Old myocardial infarction I25.2 Old myocardial infarction
413 Angina pectoris 413 Angina pectoris I20 Angina pectoris
412, 414 Chronic ischaemic heart disease,
asymptomatic ischaemic heart
disease
414 Other forms of chronic ischaemic
heart disease
I25 (excl.I25.2) Chronic ischaemic heart disease
Heart failure
427.0 Congestive heart failure 428.0 Congestive heart failure I50.0 Congestive heart failure
428.1 Left heart failure, acute oedema
of lung
I50.1 Left heart failure, acute oedema
of lung
Other cardiovascular diseases
400-404 Hypertensive disease 401 - 405 Hypertensive disease I11 - I13 Hypertensive disease
415 Acute pulmonary heart disease I26 Acute pulmonary heart disease
420-429 Other forms of heart disease 420 - 429 Other forms of heart disease I30 - I49, I51 Other forms of heart disease
426 - 427 Conduction disorders and cardiac
dysrhythmias
I44 - I49 Conduction disorders and
cardiac dysrhythmias
440 Atherosclerosis 440 Atherosclerosis I70 Atherosclerosis
441 - 442 Aortic aneurysm I71 - I72 Aortic aneurysm
444 Arterial embolism and thrombosis I74 Arterial embolism and
thrombosis
451-456 Venous thromboembolic disease 451 - 456 Venous thromboembolic disease I80-I87 Venous thromboembolic disease
Cerebro-vascular diseases
430-438 Cerebrovascular diseases 430 - 438 Cerebrovascular diseases I60 - I69, G45 Cerebrovascular diseases
430 Subarachnoid haemorrhage 430 Subarachnoid haemorrhage I60 Subarachnoid haemorrhage
431 Cerebral haemorrhage 431 Intracerebral haemorrhage I61 Intracerebral haemorrhage
431 Cerebral haemorrhage 432 Other and unspecified intracranial
haemorrhage
I62 Other non-traumatic intracranial
haemorrhage
432 Occlusion of precerebral arteries 433 Occlusion and stenosis of
precerebral arteries
I65 Occlusion and stenosis of
precerebral arteries, not
resulting in cerebral infarction
433, 434 Cerebral thrombosis, cerebral
embolism
434 Occlusion and stenosis of cerebral
arteries
I66 Occlusion and stenosis of
cerebral arteries, not resulting in
cerebral infarction
433 Cerebral thrombosis 434.9 Cerebral infarction I63 Cerebral infarction
435 Transient cerebral ischaemia 435 Transient cerebral ischaemia G45 Transient cerebral ischaemic
attacks and related syndromes
436 Acute but ill-defined
cerebrovascular disease
436 Acute, but ill-defined,
cerebrovascular disease
I64 Stroke, not specified as
haemorrhage or infarction
437, 438 Generalised ischaemic
cerebrovascular disease, other and
ill-defined cerebrovascular disease
437 Other and ill-defined
cerebrovascular disease
I67, I68 Other cerebrovascular disease,
Cerebrovascular disorders in
diseases classified elsewhere
438 Late effects of cerebrovascular
disease
I69 Sequel of cerebrovascular
diseases
*With modifications from EUROCISS Project Final Report 2006 (http://ec.europa.eu/health/ph_projects/2003/action1/docs/2003_1_10_frep_en.pdf).Penka A. Atanassova
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most deadly and life-threatening conditions
(especially in catastrophic APS), although not the
most frequent (Table 2), we present here in a
summarized form their evolving classifications in
order to compare them (Table 3).
Vascular-ischemic/occlusive diseases (VIOD) in
APS
Cardiac complications
One of the most important groups of VIODs in
APS includes those with cardiac manifestations.
For instance, intracardiac thrombi in the
ventricular cavities are reported in patients with
aPLs.
23,24 Such patients may present with systemic
or pulmonary embolic symptoms (e.g. transient
ischemic attacks (TIAs), stroke, pulmonary
infarction) depending on the location of the
thrombus (right or left ventricle; the thrombus
forms on the akinetic segments of the ventricle).
Occasionally, a clot may form even on a normal
mitral valve.
25 In other APS patients, multiple
small vascular occlusions ("thrombotic micro-
vasculopathy") develop and are responsible for
acute or chronic cardiomyopathy. Acute cardiac
collapse (with eventual respiratory decom-
pensation) is frequent in catastrophic APS and is
one of the most common causes of death in such
patients. Isolated circulatory failure has also been
reported,
26 as has renal thrombotic microangiopathy.
However, chronic cardiomyopathy may be global
or localized, whereas a segmental ventricular
dysfunction can supervene.
27 Impaired left
ventricular diastolic filling was also observed
28
and associated with cardiomyopathy or myocardial
ischaemia (the latter provoked by coronary
arteriolar occlusions). Both may lead to myocar-
dial fibrosis and a decrease in left ventricular
compliance.
Cyanotic congenital heart disease with elevated
aCL has also been reported (with thrombotic
episodes and/or thrombocytopenia).
29 At the same
time, post-surgery complications in APS have also
been reported: a hypercoagulable condition has
been detected in 10% of patients undergoing
cardiovascular surgical procedures leading to a
higher incidence of early graft thrombosis (27%
vs. 1.6%).
30 A constellation of risk factors
identified the highest-risk patient: female, young,
non-smoker, and more likely to have upper
extremity involvement than patients who were
aPL-negative.
31 Other authors
32 have found that
26% of patients were aPL-positive and were 1.8
times more likely to have undergone previous
lower-extremity vascular surgical procedures and
5.6 times more likely to have suffered occlusion
during previous reconstructions.
Osteoarticular symptomatics
The osteoarticular syndromes have shown the
highest relative cumulative frequency among all
APS complications (Table 2). It has been suggested
that the avascular necrosis (AVN) of bone in SLE
patients is probably multifactorial.
33 A possible link
between AVN and aPLs has been postulated,
34 but
the relationship is still unproven; the lack of other
risk factors points to a suspected etiological role of
antiphospholipid antibodies in AVN syndrome.
35
Dermatological appearances
The dermatological syndromes are the most
obvious signs of APS, for instance, superficial skin
necrosis,
36,37 including necrosing livedo reticularis.
38
To note, widespread cutaneous necrosis is
associated with massive thrombosis of the small
and medium-sized dermal vessels in primary
APS,
39 SLE,
40 rheumatoid arthritis,
41 and mycosis
fungoides.
42 Erythematous macules and painful
nodules have been reported in aPL-positive patients
as being due to thrombotic skin disease,
43,44 and
they can possibly improve with salicylates.
45 Nail
symptoms such as multiple subungual haemor-
rhages,
36,46 in particular with amaurosis fugax
47 or
splinter haemorrhage in general
48 or ischaemia-
provoked aPL-associated gangrene, e.g., in SLE
(different from vasculitis, cryoglobulinemia or
disseminated intravascular coagulation), have
been reported. The latter is a hallmark of the
cutaneous complications of catastrophic APS.
Additionally, other dermatological syndromes such
as anetoderma,
49,50 discoid LE
49 or intravascular
coagulation necrosis have also been observed in
aPL-positive patients. The large variety of clinical
events in aPL-positive patients differing from
underlying thrombotic lesions (e.g. chorea) su-
pports the multifactorial action of these anti-
bodies (i.e., there is possibly systemic cellular
involvement for extrapyramidal damage in anAntiphospholipid Syndrome and Ischemic Diseases
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APS patient, as recently discussed by Atanassova
and Dimitrov
51), thus suggesting that long-term
anticoagulation therapy may not be needed, at
least in these particular cases.
Pulmonary complications
A major pulmonary arterial occlusion by
thrombosis is rare;
52 pulmonary microthromboses
are also rare in aPL- positive patients.
53 This rarity
might be explained by eventual mechanical
disruption of clots in the lungs (i.e., similar to
cancer cells destroyed in lung microvasculature
54).
Adult respiratory distress syndrome (ARDS)
55 has
been reported in APS and CAPS, together with
adrenal hypofunction. This suggests a "cause and
effect" to increased cytokines following tissue
damage, possibly as a part of the so-called "systemic
inflammatory response syndrome" (SIRS). Intra-
alveolar pulmonary haemorrhage
56,57 is another
sign of APS, together with pulmonary capillaritis,
microvascular thrombi and bronchiolitis obliterates.
Fibrosing alveolitis was also reported with APS.
58
Spiking fevers, pleuritic chest pain associated with
pleural effusion and patchy infiltration (postpar-
tum syndrome) were described
15,16 as forming part
of the clinical picture of CAPS.
Renal diseases
The renal pathologies in ASP, which are due to
VIODs, are widespread with various presentations,
although they are not very common. Glomerular
capillary thrombosis in lupus nephritis
59-62 may
affect up to 48% of APS/aPL-positive patients and
is highly predictive of sclerosis progression,
possibly due to inflammatory processes. Thrombotic
microangiopathy,
63 similar in pathological
appearance to scleroderma, eclampsia, thrombotic
thrombocytopenic purpura (TTP)-hemolytic uremic
syndrome (HUS) conditions and transplant
rejection
64 may occur together with microangio-
pathic hemolytic anemia, schistocytes and
moderate to severe thrombocytopenia.
65 Such
occurrences may be observed in CAPS,
66 but in
more benign cases the differential diagnosis from
TTP may be difficult.
Adrenal pathologies
Adrenal damage has been reported with APS
67,68
even in patients only 10 years old. Recently, acute
adrenal insufficiency after such haemorrhage has
also been reported.
69 Adrenal vein thrombosis and
hemorrhagic infarction are the putative causes,
since increased adrenal venous pressure may
provoke haemorrhage into the gland.
67 In addition
to such typical vascular arrangements as the
"vascular dam",
67 stress and several other risk
factors for adrenal haemorrhage have also been
reported (e.g., severe systemic illnesses, previous
thromboembolic disease or post-surgery states).
Additionally, this complication has also been seen
in many patients who had not been on
anticoagulation therapy at all.
Hepatic syndromes
Budd-Chiari syndrome was first observed in
APS in 1984
70; since then, more cases with
obstruction of the large hepatic veins resulting in
hepatic congestion and liver cell necrosis in APS
have been reported.
71 An association of portal
hypertension (possibly due to thromboembolism/
cirrhosis) with aPLs has been found,
72,73 as well as
a correlation with pulmonary hypertension.
72
Thus, it has been suggested
74 that a thrombo-
embolism associated with aCL antibodies might
be the underlying pathological mechanism in both
conditions. Hepatic venoocclusive disease is
caused by nonthrombotic concentric narrowing of
small centrilobular veins by loose connective
tissue, congestion, and cell necrosis in the
centrilobular areas.
70 This syndrome is possibly
associated with nodular liver hyperplasia as well
as with bone marrow transplantation.
75,76 The
presence of aPLs in liver nodular regenerative
hyperplasia has been suggested
77 to result from a
venoocclusive disease or hepatic infarction and is
associated with a range of systemic autoimmune
disorders.
78 In particular, overt hepatic infarction
is rare. It has occasionally been described in APS
78
as well as during pregnancy and the postpartum
period or been associated with HELLP syndrome.
Chronic hepatitis in APS has also been reported.
79-81 Various incidences (from about 2% to 17%) of
hepatitis C virus (HCV) infection have been
observed in aCL positive thrombotic disorders.
81,82
In contrast, 33% of patients with chronic HCV
infection were found to be positive for aCL. In a
recent study, the development of APS in the
course of an HCV infection was described.
83Penka A. Atanassova
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Additionally, about half of patients with alcoholic
liver disease/a history of alcohol abuse had aCL
elevations.
82 Positive results for aPLs may range
up to as high as 80%
84 in alcoholic hepatitis or
cirrhosis patients. Notably, cirrhosis is inversely
associated with hypercoagulation by aCL; how-
ever, one half of the patients with splanchnic
thromboses (12%) in biopsy-diagnosed cirrhosis
were positive for LA or aCL. At the same time it
was found that 75% of LA patients were positive
for HCV, which further supports the possible
association between chronic HCV infection and
aPLs
85 Recently, a case of Wilson’s disease (hepa-
tolenticular degeneration) was reported along
with primary APS in a patient presenting mainly
with extrapyramidal damage.
86 The latter was
supposed to have had an autoimmune aPL
component provoking mainly recurrent arterial/
venous thrombosis and thrombocytopenia, but a
possible systemic cellular involvement by aPLs in
the central nervous system (besides thrombosis)
may have interacted with a specific genetic back-
ground.
51
Digestive manifestations
Esophageal necrosis
87 and bleeding esophageal
varices from portal vein thromboses have been
reported in APS. Gastric ulceration with necrosis
due to widespread occlusive vascular disease
88 as
well as small and large bowel vascular occlusions
in aPL-positive patients were also reported.
89,90
Gastrointestinal haemorrhage as a result of bowel
ischaemia or an atypical duodenal ulcer
91 occurs
most frequently in CAPS patients (abdominal pain
is one of the most common manifestations in such
cases). Mesenteric inflammatory vasoocclusive
disease leading to ischemic injury was associated
with APS.
92 Half of such cases are "primary" or
idiopathic; often, a family history of thromboem-
bolism suggests an inherited hypercoagulable dis-
order (in fact, a link between idiopathic mesen-
teric thrombosis and peripheral thrombosis has
been shown
93). At the same time, thromboembolic
complications of inflammatory bowel disease
were associated with aPLs (e.g., in ulcerative
colitis and Crohn's disease
94).
As mentioned above, the abdominal pain in
APS is an important initial presentation; it may
also be due to a pancreatic involvement by
microangiopathy.
95 Recently such involvement has
been reported in CAPS as well. Acute cholecystitis
has also been observed in CAPS patients.
96 Last
but not least, an occlusion of the splenic vessels
was parallel to other vascular occlusions.
97
However, splenic infarction/splenic atrophy are
rare events, although at least one SLE patient with
these complaints has been reported.
98
Malignant diseases
Although the role of malignancies in and their
associations with APS are not clear, these are the
primary causes that precipitate APS development
and progression. A recent report
99 has shown that
more than 25% of the neoplasms in patients
having aPLs are haematological malignancies
(e.g., B-cell lymphoma, spleen lymphoma, chronic
myeloid leukaemia, and non-Hodgkin’s lymphoma)
and another 27% consist of solid tumours (renal
cell carcinoma, lung adenocarcinoma, breast
carcinoma, melanoma, and primary tumours of
unknown origin). Notably, in 17 of the above 23
cases, CAPS had been possibly triggered by the
cancer; it is very important to realize that
thrombotic events associated with aPLs, especially
in elder patients, may be the initial and/or single
manifestation of the malignant disease.
Neuropsychiatric syndromes in APS
(predominant vascular-ischemic/occlusive origin)
Since the description and designation of the
antiphospholipid (Hughes) syndrome, the links
between aPLs and diseases of the nervous system
have been considered of major importance.
100
The first evidence of large peripheral arterial
occlusions in SLE patients appeared in the
1960s.
101 Such general vascular-ischemic (occlusion)
symptoms as recurring thrombophlebitis, skin
infarcts and chronic leg ulcers as well as other
arterial occlusions and TIAs were described in
these patients. During the following years, more
studies on large arterial occlusions and gangrene
in SLE patients with aPLs were published.
102,103 In
addition, an aortic arch syndrome and SLE were
also observed,
104-106 whereas a positive testing for
aPLs was found,
105 including occlusions of the
abdominal aorta in aPL-positive patients.
107,108
Since the first report by Hughes in 1983,
109 theAntiphospholipid Syndrome and Ischemic Diseases
Yonsei Med J Vol. 48, No. 6, 2007
cerebral symptomatics in APS patients have
become more and more important. Table 4
summarizes CNS manifestations: much of these
symptomatics could not be explained solely by
hypercoagulability and could have had a more
complex origin.
51,86 In many patients with chorea,
for example, focal lesions on computed tomography
(CT) scan, possibly due to thrombosis, have not
been found.
110,111 To note, aPLs may have more
direct effects; etiologically, they may bind neurons
or glial cells and disrupt their function.
112,113 There
is evidence that aPLs may interfere with endothelial
cell function and promote the procoagulant
activity of endothelial cells.
114,115 It has been
shown that IgG fractions increase mononuclear
cell adhesion to human umbilical vein endothelial
cells (HUVEC) in aPL- positive patients. Recently,
it was also reported that anti- 2GPI antibodies β
bound to and activated endothelial cells through
the adherent cofactor 2GPI. β
116 These studies
indicate that aPLs focus on the endothelium and
damage the vasculature, making it more prone to
leukocyte adhesion and thrombosis. It is not
known why the brain and CNS are particularly
vulnerable in APS patients. The aPLs involvement
in thrombosis is well evidenced, e.g., APS was
induced after immunization with aCL or 2GPI. β
117
Furthermore, immunization of BALB/c mice with
monoclonal aCL resulted in APS with neurological
dysfunction and impaired motor coordination.
118,119
Cerebrovascular disease/cerebral ischaemia
Strokes and transient ischaemic attack (TIA)
These are considered the second most common
clinical manifestations of APS after venous thro-
mbosis.
120 Cerebrovascular disease (CVD) is the
most frequent neurological manifestation in aPL-
positive patients.
121 The association between CVD
and aPLs has been described in earlier studies
122
and later confirmed by many other authors.
123,124
It was also suggested that aCL and LA represent
Table 4. APS/Neuro-Psychiatric Presentations
1. Cerebro-vascular disease
1.1 Transient ischaemic attacks
1.2 Ischaemic strokes
1.3 Acute ischaemic encephalopathy
1.4 Cerebral venous thrombosis
2. Epilepsy
3. Headache
4. Chorea
5. Multiple sclerosis
6. Transverse myelitis
7. Idiopathic intracranial hypertension
8. Other neurological syndromes
8.1 Sensori-neural hearing loss
8.2 Guillian-Barré syndrome
8.3 Transient global amnesia
8.4 Ocular syndromes
8.5 Dystonia Parkinsonism
9. Cognitive dysfunction
10. Dementia
11. Other psychiatric disorders
11.1 Depression
11.2 Psychosis
Fig. 1. Therapeutic approach to catastrophic antiphos-
pholipid syndrome (CAPS). With modifications from
Panchovska M., Atanassova P., Despotova L. Therapeutic
strategy in antiphospholipid syndrome. Rheumatology
(Sofia) 2005;13;7-13 (in Bulgarian) as based on the paper
by Asherson RA. The catastrophic antiphospholipid
(Asherson's) syndrome in 2004 - a review. Autoimmunity
Reviews 2005;4:48-54.Penka A. Atanassova
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a kind of aPLs leading to cerebral vascular injury
and thrombosis resulting in cerebral infarction.
The cerebral ischaemia, which is mainly focal, can
be transient or permanent. Recurrent disease often
leads to multifocal deficits. For instance, amaurosis
fugax,
123 transient paresthesias, motor weakness,
vertigo, and transient global ischaemia
125 can all
be expressions of TIAs, either initial or recurrent
ones, whereas the latter may occur without a
cerebral infarction. The risk for recurrent stroke
appears to be increased in APS patients. Gene-
rally, the territory of the middle cerebral artery is
more commonly affected.
126,127 A chronic multi-
focal disease can produce multi-infarct dementia.
123 This dementia, generally associated with a loss
of cognitive functions and an impairment of skills,
concentration, memory dysfunction, language
impairment and judgemental defects, as described
below, might be considered secondary if it
occurred separately, and it does not present with
peculiar characteristics.
Although not very frequent, cardiac emboli may
be another cause of cerebral ischaemia in aPL-
positive patients (cerebral emboli from Libman-
Sacks endocarditis in SLE patients
128 or from the
heart chambers or the internal carotid artery).
Cerebral ischemic events are more frequent in
patients with valvular heart disease (e.g., left-
sided valve lesions or mitral valve vegetations
and mitral regurgitation in SLE patients with aPLs
129). Brain magnetic resonance imaging (MRI) in
ischemic stroke shows cortical abnormalities
consistent with large vessel occlusion in aPL-
positive patients. Often, small foci of high signals
in the white matter of the brain are seen on MRI.
Larger sizes and atypical topographic distri-
butions of these lesions may also be consistent
with demyelination and are sometimes difficult to
differentiate from MRI pictures seen in multiple
sclerosis
130 (see below).
There have been reports on recurrent episodes
of cerebral ischaemia in patients with livedo reti-
cularis (Sneddon’s syndrome) with aPLs suggest-
ing the presence of APS.
131,132 A more rapid
progression and more severe clinical manifesta-
tions are seen in patients with increased aCL
levels. At the same time, single photon emission
computed tomography (SPECT) in livedo reti-
cularis without focal neurological deficits indicat-
ed deficits of cerebral perfusion suggestive of
increased risk of Sneddon’s syndrome.
133 This
association between livedo and ischemic stroke,
occasionally with hypertension, has been known
since 1965.
134 The syndrome is more frequent in
women, and it is usually diagnosed between 40-50
years of age. A familial clustering is suggestive for
a primary APS.
135 Early inflammatory reactions
(endothelitis) of the small arteries occur as
followed by subendothelial cell proliferation lead-
ing to partial or complete occlusion.
136 Therefore,
there is accumulating evidence in support of the
association (Sneddon’s syndrome) not only in SLE
and/or APS but in the general population as well.
However, these results are contradictory; most
studies revealed an association of aPLs with an
increased risk of cerebral ischaemia,
137,138 but
others did not.
139 Some of the results showed that
the presence of IgG 2GPI-dependent aCL was β
characterized by a two-fold increase in the odds
of stroke within 15 years versus aCL-negative
patients. Antiphosphatidylserine antibodies were
also associated with an increased risk for ischemic
stroke in the general population.
140 As previously
mentioned, other studies have not confirmed the
presence of aCL and LA with repeated testing,
although it is well known that aCL and LA can
vary over time (especially during the acute phase
of thrombotic events).
141 Moreover, neither aCL
ELISA nor any cut-off values have all been
standardized. However, it is recommended that
aPLs should be confirmed again at least one to
three months after the thrombotic event.
Recurrent ischemic events in aPL-positive pati-
ents are related to aCL at the time of the initial
stroke. In consecutive patients with aPLs and focal
cerebral ischaemia,
142 cerebral infarctions within
the first follow-up year supported the data that
IgG aCL represented a risk factor for recurrent
stroke. In a later study
126 this was confirmed, and
the subsequent thrombo-occlusive events were
associated with IgG aCL (most frequently in
patients with aCL 40 GPL), thus confirming the
role of aCL as a risk factor for recurrent stroke.
Other studies
143 included patients with lower
levels of aCL (>10 GPL) who were at lower risk
of thrombotic events, but their population was
older, with other cardiovascular risk factors that
minimized the relative impact of aCL on recurrentAntiphospholipid Syndrome and Ischemic Diseases
Yonsei Med J Vol. 48, No. 6, 2007
stroke. To note, the above positive relationships
are probably most relevant to younger popu-
lations with evidence of prothrombotic tendencies
and little other risk of stroke.
Additionally, acute ischemic encephalopathy
has also been observed but is a rare feature in SLE
patients with aPLs. Patients are acutely ill,
confused and have asymmetrical quadriparesis,
hyper-reflexia, and bilateral extensor plantar
responses.
144 Seizures may also occur; small cor-
tical hypodensities are evident on MRI scanning
in such patients. The differential diagnosis lies
between acute lupus cerebritis and even steroid
psychosis in those with predominantly frontal
lobe symptomatology. It is likely that cerebral
thrombotic microangiopathy may lead to such
acute ischemic encephalopathy as can occur
within a catastrophic APS. Additionally, cerebral
venous thrombosis is another uncommon appe-
arance in APS but it may be involved in a range
of hypercoagulable states,
145 especially in young
women.
146
Transient global amnesia
Sudden, unexplained short-term memory loss
was associated with aPLs.
147 This was due to
migrainous etiology, however, and epileptic seizures
were considered pathogenic.
148 Often associated
with stereotypical behaviour, the transient global
amnesia was related to aPL-linked ischaemia.
147
Headache
One of the most common features in patients
with APS is headache, which can vary from classic
intermittent migraines to almost continuous
incapacitating states. However, the results are
controversial; demonstrating a true association
between aCL positivity and migraine is difficult
since (i) there is a high frequency of migraine in
normal individuals and (ii) a relatively low
frequency of aCL in healthy populations. aPLs
were also observed in transient neurological
symptoms, including migraine with aura. The
available data suggest an association between the
migraine-like phenomena and aPLs, but not
between migraine headache and aPLs. A
prospective study
149 failed to find an association
between the presence of aCL and migraine.
Notably, aPLs, especially IgG aCL, is associated
with chronic headache in SLE patients, but not
with a particular subtype of headache or with
migraines.
150 For instance, both the aforemen-
tioned cerebral venous sinus thromboses and the
dural ones have a diverse spectrum of clinical
manifestations, the most common being headache
accompanied by papilledema, nausea, vomiting,
and visual field loss. The cerebral thrombosis
leads to a syndrome called "pseudotumour cerebri"
(benign intracranial hypertension), which is
mainly idiopathic and associated with impaired
cerebrospinal fluid dynamics.
146,151,152
Epilepsy
Increased aPLs in SLE patients with seizures
were found as being higher than the accepted
prevalence in SLE.
153 It was suggested.
154 that
seizures in aPLs were due to ischemic events
occurring in hypercoagulability (seizures are a
well-known symptom of cerebral ischaemia
155).
Earlier studies
156 found a high prevalence of aPLs
in SLE patients with seizures compared with
controls, providing evidence that the IgG isotype
of aCL may have a pathogenic role in SLE-
associated epilepsy. This was confirmed later
157
with an odds ratio of 3.7 versus no aCL. Another
trial
158 described in detail the brain injury seen in
SLE patients with APS, finding frequent epilepsy
(and stroke) with an increase of thrombotic and
non-thrombotic brain injures. Angelini et al.
159
suggested that aPLs play a role in the immune-
mediated pathogenic mechanism for partial epile-
psy. Verrot et al.
160 reported that aCL was present
in 20% of patients and was independent of the
type of epilepsy, the antiepileptic treatment, or the
age or sex of the patients. These findings were
later confirmed
161 by showing that the prevalence
of aPLs was greater in patients with epilepsy,
including those with newly-diagnosed seizure
disorders. The prevalence of IgG aCL in localiza-
tion-related epilepsy was almost twice that in
generalized epilepsy, and IgM aCL was higher as
well, indicating an immune dysregulation in
epilepsy. The aCL-brain phospholipid interaction
in SLE may be expressed through a direct rever-
sible mechanism by which aPLs lower the seizure
threshold.
162 It was also reported that aPLs might
bind directly to the ependyma and myelin in the
brains of animals.
163Penka A. Atanassova
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Ocular syndromes
Ocular vascular-occlusive diseases
Ocular syndromes are frequent in APS
patients.
164 Amaurosis fugax is one of the most
common appearances. Optic neuropathy (acute
retrobulbar optic neuritis, ischemic optic atrophy
and progressive optic atrophy) is a well-known
ocular impairment occurring in SLE patients, and
it remains one of the major causes of blindness.
Bilateral optic neuropathy in SLE occurs more
frequently than the monolateral form. It is
associated with transverse myelitis,
165 particularly
in SLE patients with Devic’s syndrome (probably
due to such immunological mechanisms as
vasculitis). Optic neuropathy was also linked with
the presence of aPLs.
166 Several reports have
estimated that retinal vascular occlusions occur in
up to 12% of aPL- positive patients.
167 In addition,
optic neuropathy was less frequent in APS
patients without SLE and tended to be
monolateral in these cases. Monolateral occurrences
of optic neuropathy are considered a focal
neurological disease
168 due to a thrombotic event
involving the ciliary vasculature. Small vessel
occlusions affecting the choroid, retina, and optic
nerve lead to ischaemia and even infarctions.
Neovascularization may provoke secondary
vitreous haemorrhage, traction retinal detachments
or glaucoma.
169
Cognitive dysfunctions
As shown above, seizures and transverse
myelopathy, as well as affective disorders and
cognitive impairments (see further), are also
linked with aPLs.
170 APS patients with severe
impairments and rapidly progressive changes in
mental status, memory disorders, confusion, and
emotional lability were reported.
171 Cognitive
impairments range from multi-infarct dementia to
subtle deficits in asymptomatic patients with
aPLs. Poor memory, difficulty in concentrating or
difficulty keeping attention focused for a long
time are most frequent and indicate a probable
preclinical phase of neurological involvement. The
recognition of subtle cognitive dysfunctions was
made possible by formal neuropsychological
assessments in a number of trials, mainly in
patients with SLE, and it has helped identify the
primary etiological role of aPLs.
Dementia
Recurrent or progressive neurological deteriora-
tions due to cerebrovascular disease can produce
multi-infarct dementia (i.e., chronic multifocal
disease). This was first reported in 1987, and 35
aPL-positive patients with cerebrovascular disease
were described in 1989.
123 Dementia, which is
generally associated with a loss of cognitive
functions and an impairment of skills, poor
concentration, memory dysfunction, language
impairment, and judgemental defects, was not
peculiar and is difficult to distinguish from
Alzheimer’s disease, senile dementia, or other
metabolic or toxic brain conditions. Later, how-
ever, brain biopsy findings from a patient with
multi-infarct dementia and APS were published.
172
Luminal occlusion by thrombi and marked
endothelial hyperplasia of the small meningeal
and cortical arterioles were found, suggesting a
noninflammatory etiology associated with reactive
endothelial hyperplasia and thrombosis of the
small arterioles. In another study,
121 cerebral
atrophy and white matter hyperintensities were
detected on MRI, whereas positron emission
tomography (PET) scans showed a considerable,
diffuse impairment of cortical glucose metabolism
combined with a reduced cerebral perfusion in
arterial border zones. These findings indicate that
primary APS-associated vascular dementia may
be due to cortical neuronal losses as caused by
small vessel disease with immune-mediated
intravascular thrombosis. The investigation of the
link between aPLs and dementia
173 indicated that
6% of patients had significantly elevated aCL IgG
levels (> 20 GPL). All these patients had dementia
similar to that seen in Alzheimer’s except for one
who had mixed dementia, but none of them had
an immune-mediated disorder. Therefore, a signi-
ficant number of patients with dementia were
shown to have had high levels of aPLs.
Movement disorders
Chorea
A strong relationship between aPLs and chorea
has been reported in retrospective studies,
especially in SLE, but the occurrence of chorea in
SLE is usually rare (1 - 3%). Chorea has also been
documented in cases of pregnancy and as a
complication of oral contraceptives.
174 Chorea isAntiphospholipid Syndrome and Ischemic Diseases
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more frequent in primary APS than in SLE, with
a vascular pathogenesis being most probable. It
has been proposed that aPLs can provoke chorea
by an antigen/antibody mechanism by binding
with phospholipids in the basal ganglia.
175 In a
review study of 50 patients with chorea and
APS,
17 SLE was found in 58% of the patients,
primary APS-in 30%, and the rest 12% of the
studied patients suffered from a ‘lupus-like’
syndrome while, in the same time, the chorea was
bilateral in 55% of the total patient population.
Cerebral infarcts on CT/MRI scans were found in
35% of the patients. It is difficult to distinguish the
chorea in APS from the chorea encountered with
rheumatic fever (Sydenhan’s) or the inherited
form (Huntington's). Chorea may appear without
any obvious precipitating factors or be induced by
oral contraceptive use (Cervera et al. reported in
the above review
17 that 96% of patients were
females with a mean age of 23 years). A single
episode of chorea was observed in 66% of
patients, while in 34% it was recurrent (the chorea
was seen bilaterally or monolaterally as starting
occasionally on one side and reappearing on the
other one). CT patterns are usually normal, but
infarcts outside the basal ganglia themselves were
seen. MRI findings were reported in 13 out of 50
cases, and three infarcts were seen in the caudate
nuclei. Reversible immune-mediated response was
the most likely pathogenesis of chorea,
176 but a
vascular hypothesis with thrombosis and infarc-
tion could not be excluded. The binding of auto-
antibodies to striatal interneurons may cause
hypermetabolic dysfunction of these cells, notably,
a striatal hypermetabolism has been described.
176
Additionally, beyond chorea, hemiballismus in an
aCL-positive patient was described,
177 along with
a cerebellar ataxia with aPL positivity.
178
Dystonia-Parkinsonism
Basal ganglial involvement is often confirmed
on MRI; notably, Milanov and Bogdanova
179
reported an occurrence of primary APS with
marked dystonic posturing, rigidity, bradykinesia,
several hyperintense lesions in the basal ganglia
and in the periventricular white matter, and
diffuse hyperintensity of the subcortical white
matter, bilaterally in the parietal regions.
Psychoses
Several cases were recorded where psychosis
preceded the thrombotic symptoms in APS by
many years.
180 Indeed, increased aPL levels have
been reported in schizophrenic patients
181 as well
as in those with a major depressive illness.
182
However, aPL involvement was not well defined,
although aPLs may be primarily associated with
psychosis (i.e., the patients were not known to
have autoimmune disorders but only acute
psychosis).
Other neurological disorders in APS
The previous neurological complications in APS
were shown to have mainly an ischemic-throm-
botic origin, but a possible cellular involvement
by aPLs and/or a specific interplay between
immunologic and genetic factors in the central
nervous system (CNS) could not be excluded. As
emphasized elsewhere,
51 a specific genetic back-
ground with autoimmune mechanisms may have
been involved not only in the recently reported
case of Wilson’s disease in APS with predominant
extrapyramidal symptomatics,
86 but also in the
aforementioned dystonia, Parkinsonism,
179 or
other neurological disorders. Such diseases in
APS, with ischaemia and/or direct neural/neuro-
nal tissue damage by antibody-mediated inter-
actions, are separately described in the following
sections.
Multiple sclerosis (MS)
Clinical manifestations and CNS imaging
characteristics for MS with APS patterns and
responses to anticoagulant therapy have been
described.
130,183 It was recommended that
anticoagulation therapy should be considered in
MS with persistent aCL at medium-high levels
and/or LA, especially those with atypical MS
forms, previous thromboses, obstetric complica-
tions, thrombocytopenia, and/or lupus.
184 A rare
syndrome of "lupoid sclerosis" was described with
symptoms resembling MS and laboratory findings
suggestive of SLE (e.g., spastic paraplegia
185).
Another finding is the so called "pseudo-multiple
sclerosis" in aPL-positive patients in which the
distinction between the conditions may be difficult
(i.e., young patients with fluctuating/recurrentPenka A. Atanassova
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neurological events and focal/visual neurological
symptoms). In such patients high signal lesions in
the periventricular white matter on T2-weighted
images resembled those seen in MS.
186
In 1994, four patients with multiple neurological
manifestations of MS (including white matter
lesions, vertigo, aphasia, unilateral visual loss,
diplopia or hemiparesis) were reported over
several years with variable degrees of recovery
after the episodes.
187 IgG aCL were positive in all,
and LA was also found in three of the four
patients. More recent studies showed a contro-
versial relationship between MS and aPLs.
Patients with MS-like illnesses and aPLs
130 were so
similar to other MS patients that they should not
be excluded from clinical trials.
188 A study in
1998
183 found a large, significant proportion of
aCL-positive patients in non-classic MS (with
similar patterns including progressive myelopa-
thy, spinocerebellar syndrome, or neuromyelitis
optica). Subsequently, aCL testing with an eventual
anticoagulant approach was recommended in MS
patients showing slower progressions and some
atypical features (persistent headaches, absence of
oligoclonal bands). Patients with probable MS
presented with underlying connective tissue
disease, uncommon findings for MS on MRI, an
atypical evolution of MS, or aPL positivity.
130
However, neither special examinations nor other
laboratory findings or MRI were useful to
distinguish APS from MS (primary APS responded
to oral anticoagulants, while the outcome in
secondary APS was not as favorable).
Transverse myelitis
The prevalence of aPLs has been shown to be
higher in SLE patients with transverse myelitis
compared with SLE patients in general.
2 A
study
189 reported 10 of 12 patients with transverse
myelitis and SLE as having aCL, and the other
two exhibited evidence of venereal disease
research laboratory (VDRL) positivity and
prolonged activated partial thromboplastin time
(aPTT). Both IgG and IgM isotype aCL were
detected in 8 of the 10 patients. The authors
concluded that there is a strong association
between transverse myelitis in SLE and the
presence of aPLs. Another report
190 described a
patient with refractory hiccups as the heralding
symptom of transverse myelitis in association
with aCL. Additionally, 14 patients with SLE and
transverse myelitis were evaluated,
191 and 91
additional cases were published in the literature.
Forty-three percent of their patients and 64% of
the patients reported in the literature were
aPL-positive, confirming the strong association of
transverse myelitis with aPLs. The presentation of
myelitis is usually acute, with paraesthesia in the
legs that ascends to the thorax within 24 to 48
hours. Paraplegia, back pain, and loss of sphincter
control may follow.
192 Several other papers have
also shown its occurrence in the presence of
aPLs.
189,193 Optic neuritis may occur simultane-
ously with transverse myelitis, presenting with
rapid visual loss accompanied by orbital pain.
194
At the same time, the pathophysiology of spinal
cord damage in aPL-associated myelopathy is
uncertain: both ischaemia and an antibody-
mediated interaction have been postulated (e.g.
one patient with anterior spinal artery syndrome
presented with a flaccid paraplegia, sphincter
disturbances, and dissociated sensory impairment
as being positive for aCL
195).
Idiopathic intracranial hypertension
Idiopathic intracranial hypertension, also known
as pseudotumour cerebri, is the term used to
describe the occurrence of raised intracranial
pressure that is not due to mass lesions,
obstruction of cerebrospinal fluid flow, or focal
structural abnormalities in alert and oriented
patients. The term idiopathic excludes the
possibility of intracranial venous sinus thrombosis.
Idiopathic intracranial hypertension is frequently
associated with aCL and can be the only
presenting symptom of APS. The association of
idiopathic intracranial hypertension with aPLs has
been acknowledged only recently.
196 However, its
actual incidence is still unknown. A previous
report
197 described 11 out of 38 patients (29%)
with both aPLs and idiopathic intracranial
hypertension. However, only four had aCL without
other prothrombotic risk factors or evidence of
sinus thrombosis. Another study
198 found aCL in
six out of 14 patients (43%) with idiopathic
intracranial hypertension. No differences were
found in clinical, laboratory, or radiological
findings that distinguished between patients withAntiphospholipid Syndrome and Ischemic Diseases
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idiopathic intracranial hypertension in those with
and without aCL. A retrospective study
199 con-
firmed the association between idiopathic
intracranial hypertension and aCL, although they
also found a lower frequency of aCL in their
patients. Three out of 37 patients (8.1%) were
shown to be aCL positive, with a prevalence lower
than that reported in the two previously published
studies.
Sensori-neural hearing loss
A link between sensori-neural hearing loss and
autoimmune disease has been postulated by many
authors who have described the association
between sensori- neural hearing loss and aPLs in
several reports.
200,201 An instance of sensori-neural
hearing loss in a young woman diagnosed with
SLE has also been presented.
200 Serological tests
for syphilis were false-positive and were positive
for IgG aCL. The authors postulated the association
of sudden profound sensori-neural hearing loss
with aCL in patients with autoimmune diseases.
Another woman, age 55, with a six-year history of
Sj gren’s syn ӧ drome who presented with IgG and
IgM aCL elevations and developed a sudden onset
of sensori-neural hearing loss associated with
vertigo was also described.
201 Another report
202
described 30 patients, 11 of whom suffered from
sudden deafness and 19 of whom presented with
progressive sensori-neural hearing loss and had
been matched to 20 healthy controls. It was found
that 27% of the patients had low to moderate
titers of aCL, while none of the control group
presented with aCL. The authors concluded that
aPLs may play an important role in the
pathogenesis of this disability and speculated
about the possibility of anticoagulant therapy for
these patients. Six patients with SLE or a lupus-
like syndrome have also been described,
203 who
developed sudden sensori-neural hearing loss
with elevated serum levels of aCL or LA. An
acute onset of sensori- neural hearing loss in the
presence of aPLs may be a manifestation of APS,
therefore, anticoagulation treatment was reco-
mmended for these patients.
Guillain-Barré syndrome
Guillain-Barré syndrome is a transient neurolo-
gical disorder characterized by inflammatory
demyelination of peripheral nerves. Although the
pathogenesis of this disorder is not clear, there is
increasing evidence for an autoimmune etiology.
This demyelinating neuropathy, also uncommon
in SLE, was associated with aPLs in the original
description of Hughes syndrome. A later study
204
reported on the reactivity of Guillain-Barré
syndrome sera with various phospholipids, which
are important constituents of myelin and serve as
autoantigens in other autoimmune conditions,
thus demonstrating that some Guillain-Barré syn-
drome patients produce autoantibodies to various
phospholipids and nuclear antigens. However,
these autoantibodies are probably produced as a
result of the myelin damage and are not the cause
of demyelination.
THERAPIES IN APS
Discussion of therapeutic approaches in APS is
beyond the scope of this overview, but most
recent advances, especially in CAPS which is the
most life-threatening variant of APS, are listed
briefly as follows:
- The main therapy of APS is anticoagulant/
antiaggregant medication.
205 Corticosteroids
may be useful in haematological manifesta-
tions (thrombocytopenia, hemolytic anemia,
myelopathy and CAPS);
206
- Prevention of recurrent thrombosis is achieved
by prolonged oral anticoagulation.
206 Intensive
therapy to a target internal normalized ratio
(INR) higher than 3.0 is most effective. How-
ever, even in INRs<3.0, no short-term recurrences
in patients with venous thromboembolism and
low-titer aCL were reported;
207
- The optimal approach to recurrent pregnancy
loss in APS may consist of a combination of
aspirin and heparin,
208 but the results are
controversial.
205 The best mode of application
would be to give low-dose aspirin to women
with recurrent early miscarriage and to add
low-molecular weight heparin to those with
fetal losses or a history of previous throm-
bosis.
High-intensity anticoagulation is recommended
as a standard for preventing thrombotic recu-
rrences in APS with a lower intensity in patientsPenka A. Atanassova
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at high risk of bleeding or at low risk of severe
thrombosis.
205,209-211
CONCLUSION
The nature of APS, as well as the evolving
symptomatology of SLE, contributed to the reco-
gnition that anticoagulating approaches, rather
than steroids or immunosuppressive drugs, signi-
ficantly improved the outcome in a substantial
number of patients with APS. We may also
conclude that CNS disease in SLE is significantly
associated with aPLs. Cerebral ischaemia due to
vessel occlusion is considered the most important
cause of CNS diseases in SLE, and aPLs play an
important role in their pathogenesis. There is a
strong association between aPLs and CVD,
headache, cognitive dysfunction, and seizures,
thus supporting the importance of occlusive
vasculopathies in neuro-psychiatric lupus. Hence,
testing for aPLs should be recommended not only
for patients with autoimmune diseases and
neuropsychiatric syndromes but also for younger
patients (age < 40 years) without an underlying
autoimmune disease who develop ischemic cere-
bral events and may have ‘non-classic’ MS,
transverse myelitis, or atypical seizures. During
brain MRI, such young individuals with multiple
hyperintensity lesions without other known
causes should also undergo testing for aPLs.
All patients with a target INR > 3.0 and cerebral
ischaemia should undergo anticoagulation thera-
py to prevent recurrences. All patients with
thrombosis associated with aPLs should undergo
long-term (life-long) warfarin therapy. Unfortun-
ately, low-dose aspirin alone does not prevent
recurrent thrombosis. Additionally, oral antico-
agulation carries an increased risk of serious
haemorrhage; however, this risk, if well con-
trolled, might be lowered to acceptable levels.
Steroids and immunosuppressive drugs in aPL-
positive patients and thrombosis may be justified
only in life-threatening situations when episodes
of thrombosis occur despite adequate anticoagula-
tion treatment. In aPL-positive patients without
previous thrombosis, low-dose aspirin (75 mg/
day) indefinitely as a thromboprophylactic measure
is recommended. In neuropsychiatric appearances
different from CVD (e.g., headache, seizures),
anticoagulation therapy should be considered for
patients with more severe disease and
unsatisfactory responses to traditional treatments
for headache or conventional anti-epileptic drugs.
The most important points of our study are:
1. Newly suggested improvements in the Sappo-
ro criteria for APS (Hughes syndrome) should
be widely adopted.
2. APS appears as a recurrent thrombosis,
obstetric complications and elevated serum
aPL levels:
a. The similar prevalence of arterial and
venous thrombosis in APS is a unique
pattern among thrombophilic disorders.
b. Pregnancy/fetal complications are hallmarks
of APS.
3. Neurological diseases (e.g., stroke, TIA),
possibly due to vascular-ischemic (occlusive)
disturbances, are the most life-threatening
conditions, especially in CAPS and/or when
recurrences appear. Other neuropsychiatric
disorders (e.g., cognitive impairment, certain
forms of migraine/headache, MS-like diseases)
are also associated with APS.
4. Diagnosis and routine testing of APS should
be done by 2GPI-dependent ELISA for aCL β
and LA.
5. Definite APS is diagnosed according to the
persistency of aCL (high to medium concen-
trations) and/or LA.
6. The role of other antiphospholipid antibodies
(e.g., phosphatidylserine, 2GPI, prothrombin, β
etc.) in APS, although not well defined, is likely
to have a certain clinical significance;
7. Prolonged, even life-long oral anticoagula-
tion at a target INR of 3.5 is the treatment of
choice in thrombotic APS (e.g., warfarin);
8. Aspirin and heparin are recommended as
treatments for pregnancy complications; cor-
ticosteroids, although considered life-saving
in thrombocytopenia, hemolytic anemia and/
or CAPS, do not have a decisive role in the
treatment of other APS complications.
9. New approaches have been applied in APS
such as fresh frozen plasma use during
plasma exchange, rituximab therapy, anti-
cytokine treatment, recombinant human-
activated protein C, among others, but moreAntiphospholipid Syndrome and Ischemic Diseases
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first-level evidence is needed to make defini-
tive recommendations.
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